RESUMEN
Suramin is one of the first drugs developed in a medicinal chemistry program (Bayer, 1916), and it is still the treatment of choice for the hemolymphatic stage of African sleeping sickness caused by Trypanosoma brucei rhodesiense. Cellular uptake of suramin occurs by endocytosis, and reverse genetic studies with T. b. brucei have linked downregulation of the endocytic pathway to suramin resistance. Here we show that forward selection for suramin resistance in T. brucei spp. cultures is fast, highly reproducible and linked to antigenic variation. Bloodstream-form trypanosomes are covered by a dense coat of variant surface glycoprotein (VSG), which protects them from their mammalian hosts' immune defenses. Each T. brucei genome contains over 2000 different VSG genes, but only one is expressed at a time. An expression switch to one particular VSG, termed VSGSur , correlated with suramin resistance. Reintroduction of the originally expressed VSG gene in resistant T. brucei restored suramin susceptibility. This is the first report of a link between antigenic variation and drug resistance in African trypanosomes.
Asunto(s)
Resistencia a Medicamentos/inmunología , Glicoproteínas Variantes de Superficie de Trypanosoma/genética , Animales , Variación Antigénica/inmunología , Genoma , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/inmunología , Suramina/metabolismo , Suramina/farmacología , Trypanosoma brucei brucei/genética , Tripanosomiasis Africana/tratamiento farmacológico , Glicoproteínas Variantes de Superficie de Trypanosoma/metabolismoRESUMEN
A series of novel benzimidazole diamidines were prepared from the corresponding dicyano analogues either by applying Pinner methodology (5a-c, 10 and 13a) or by making amidoximes intermediates that were reduced to the corresponding amidines (15a-c). The new amidines were evaluated in vitro against the protozoan parasite Trypanosoma brucei rhodesiense (T. b. r.). The thiophene analogue 5b and the N-methyl compound 15a showed superior antitrypanosomal activity compared to that of the parent I.
Asunto(s)
Amidinas/farmacología , Bencimidazoles/farmacología , ADN/efectos de los fármacos , Indoles/farmacología , Tripanocidas/farmacología , Trypanosoma brucei rhodesiense/efectos de los fármacos , Amidinas/síntesis química , Amidinas/química , Animales , Bencimidazoles/síntesis química , Bencimidazoles/química , Sitios de Unión/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Indoles/síntesis química , Indoles/química , Estructura Molecular , Mioblastos/efectos de los fármacos , Pruebas de Sensibilidad Parasitaria , Ratas , Relación Estructura-Actividad , Tripanocidas/síntesis química , Tripanocidas/químicaRESUMEN
2-(2-Benzamido)ethyl-4-phenylthiazole (1) was one of 1035 molecules (grouped into 115 distinct scaffolds) found to be inhibitory to Trypanosoma brucei, the pathogen causing human African trypanosomiasis, at concentrations below 3.6µM and non-toxic to mammalian (Huh7) cells in a phenotypic high-throughput screen of a 700,000 compound library performed by the Genomics Institute of the Novartis Research Foundation (GNF). Compound 1 and 72 analogues were synthesized in this lab by one of two general pathways. These plus 10 commercially available analogues were tested against T. brucei rhodesiense STIB900 and L6 rat myoblast cells (for cytotoxicity) in vitro. Forty-four derivatives were more potent than 1, including eight with IC50 values below 100nM. The most potent and most selective for the parasite was the urea analogue 2-(2-piperidin-1-ylamido)ethyl-4-(3-fluorophenyl)thiazole (70, IC50=9nM, SI>18,000). None of 33 compounds tested were able to cure mice infected with the parasite; however, seven compounds caused temporary reductions of parasitemia (⩾97%) but with subsequent relapses. The lack of in vivo efficacy was at least partially due to their poor metabolic stability, as demonstrated by the short half-lives of 15 analogues against mouse and human liver microsomes.
Asunto(s)
Amidas/farmacología , Aminas/farmacología , Antiprotozoarios/farmacología , Tiazoles/farmacología , Trypanosoma brucei rhodesiense/efectos de los fármacos , Urea/farmacología , Amidas/química , Aminas/síntesis química , Aminas/química , Animales , Antiprotozoarios/síntesis química , Antiprotozoarios/química , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Microsomas Hepáticos/química , Microsomas Hepáticos/metabolismo , Estructura Molecular , Mioblastos/efectos de los fármacos , Pruebas de Sensibilidad Parasitaria , Ratas , Relación Estructura-Actividad , Tiazoles/síntesis química , Tiazoles/química , Urea/análogos & derivados , Urea/químicaRESUMEN
Human African trypanosomiasis (HAT), a neglected tropical disease, is fatal without treatment. Pentamidine, a cationic diamidine, has been used to treat first-stage (hemolymphatic) HAT since the 1940s, but it is ineffective against second-stage (meningoencephalitic, or central nervous system [CNS]) infection. Novel diamidines (DB75, DB820, and DB829) have shown promising efficacy in both mouse and monkey models of first-stage HAT. However, only DB829 cured animals with second-stage infection. In this study, we aimed to determine the mechanisms underlying the differential efficacies of these diamidines against HAT by conducting a comprehensive pharmacokinetic characterization. This included the determination of metabolic stability in liver microsomes, permeability across MDCK and MDR1-MDCK cell monolayers, interaction with the efflux transporter MDR1 (P-glycoprotein 1 or P-gp), drug binding in plasma and brain, and plasma and brain concentration-time profiles after a single dose in mice. The results showed that DB829, an azadiamidine, had the highest systemic exposure and brain-to-plasma ratio, whereas pentamidine and DB75 had the lowest. None of these diamidines was a P-gp substrate, and the binding of each to plasma proteins and brain differed greatly. The brain-to-plasma ratio best predicted the relative efficacies of these diamidines in mice with second-stage infection. In conclusion, pharmacokinetics and CNS penetration influenced the in vivo efficacies of cationic diamidines against first- and second-stage HAT and should be considered when developing CNS-active antitrypanosomal diamidines.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Amidinas/farmacocinética , Pentamidina/farmacocinética , Tripanocidas/farmacocinética , Trypanosoma brucei rhodesiense/efectos de los fármacos , Amidinas/metabolismo , Amidinas/farmacología , Animales , Benzamidinas/metabolismo , Benzamidinas/farmacocinética , Benzamidinas/farmacología , Barrera Hematoencefálica , Línea Celular , Perros , Furanos/metabolismo , Furanos/farmacocinética , Furanos/farmacología , Células de Riñón Canino Madin Darby , Masculino , Ratones , Pentamidina/metabolismo , Pentamidina/farmacología , Unión Proteica , Tripanocidas/metabolismo , Tripanocidas/farmacología , Tripanosomiasis Africana/tratamiento farmacológico , Tripanosomiasis Africana/parasitologíaRESUMEN
African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness.
Asunto(s)
Amidinas/farmacología , Piridinas/farmacología , Tripanocidas/farmacología , Trypanosoma brucei gambiense/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológico , Amidinas/síntesis química , Amidinas/farmacocinética , Animales , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Melarsoprol/farmacocinética , Melarsoprol/farmacología , Ratones , Pentamidina/farmacocinética , Pentamidina/farmacología , Piridinas/síntesis química , Piridinas/farmacocinética , Relación Estructura-Actividad , Tripanocidas/síntesis química , Tripanocidas/farmacocinética , Trypanosoma brucei gambiense/crecimiento & desarrollo , Trypanosoma brucei gambiense/patogenicidad , Trypanosoma brucei rhodesiense/crecimiento & desarrollo , Trypanosoma brucei rhodesiense/patogenicidad , Tripanosomiasis Africana/parasitologíaRESUMEN
Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. Six compounds had antitrypanosomal IC50 values below 10 nM. Twelve analogues showed similar antiplasmodial activities, including three with sub-nanomolar potencies. Forty-four diamidines (including 16 aza-analogues) and the 26 prodrugs were evaluated for efficacy in mice infected with T. b. rhodesiense STIB900. Six diamidines cured 4/4 mice at daily 5 mg/kg intraperitoneal doses for 4 days, giving results far superior to pentamidine and furamidine. One prodrug attained 3/4 cures at daily 25 mg/kg oral doses for 4 days.
Asunto(s)
Antiprotozoarios/uso terapéutico , Isoxazoles/síntesis química , Plasmodium falciparum/efectos de los fármacos , Profármacos/uso terapéutico , Tripanosomiasis Africana/tratamiento farmacológico , Animales , Antiprotozoarios/farmacología , Isoxazoles/química , Isoxazoles/farmacología , Ratones , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Human African trypanosomiasis (HAT, also called sleeping sickness), a neglected tropical disease endemic to sub-Saharan Africa, is caused by the parasites Trypanosoma brucei gambiense and T. brucei rhodesiense. Current drugs against this disease have significant limitations, including toxicity, increasing resistance, and/or a complicated parenteral treatment regimen. DB829 is a novel aza-diamidine that demonstrated excellent efficacy in mice infected with T. b. rhodesiense or T. b. brucei parasites. The current study examined the pharmacokinetics, in vitro and in vivo activity against T. b. gambiense, and time of drug action of DB829 in comparison to pentamidine. DB829 showed outstanding in vivo efficacy in mice infected with parasites of T. b. gambiense strains, despite having higher in vitro 50% inhibitory concentrations (IC50s) than against T. b. rhodesiense strain STIB900. A single dose of DB829 administered intraperitoneally (5 mg/kg of body weight) cured all mice infected with different T. b. gambiense strains. No cross-resistance was observed between DB829 and pentamidine in T. b. gambiense strains isolated from melarsoprol-refractory patients. Compared to pentamidine, DB829 showed a greater systemic exposure when administered intraperitoneally, partially contributing to its improved efficacy. Isothermal microcalorimetry and in vivo time-to-kill studies revealed that DB829 is a slower-acting trypanocidal compound than pentamidine. A single dose of DB829 (20 mg/kg) administered intraperitoneally clears parasites from mouse blood within 2 to 5 days. In summary, DB829 is a promising preclinical candidate for the treatment of first- and second-stage HAT caused by both Trypanosoma brucei subspecies.
Asunto(s)
Amidinas/farmacología , Tripanocidas/farmacología , Trypanosoma brucei gambiense/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológico , Amidinas/farmacocinética , Animales , Esquema de Medicación , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Inyecciones Intraperitoneales , Melarsoprol/farmacología , Ratones , Pruebas de Sensibilidad Parasitaria , Pentamidina/farmacología , Factores de Tiempo , Tripanocidas/farmacocinética , Trypanosoma brucei gambiense/crecimiento & desarrollo , Trypanosoma brucei rhodesiense/crecimiento & desarrollo , Tripanosomiasis Africana/parasitologíaRESUMEN
Dicationic 2,6-diphenylpyrazines, aza-analogues and prodrugs were synthesized; evaluated for DNA affinity, activity against Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium falciparum (P. f.) in vitro, efficacy in T. b. r. STIB900 acute and T. b. brucei GVR35 CNS mouse models. Most diamidines gave poly(dA-dT)2 ΔTm values greater than pentamidine, IC50 values: T. b. r. (4.8-37nM) and P. f. (10-52nM). Most diamidines and prodrugs gave cures for STIB900 model (11, 19a and 24b 4/4 cures); 12 3/4 cures for GVR35 model. Metabolic stability half-life values for O-methylamidoxime prodrugs did not correlate with STIB900 results.
Asunto(s)
Antiprotozoarios/síntesis química , Compuestos Aza/química , Pentamidina/química , Profármacos/síntesis química , Pirazinas/química , Animales , Antiprotozoarios/uso terapéutico , Antiprotozoarios/toxicidad , Cationes/química , Línea Celular , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Ratones , Mioblastos/citología , Pruebas de Sensibilidad Parasitaria , Pentamidina/uso terapéutico , Pentamidina/toxicidad , Plasmodium falciparum/efectos de los fármacos , Poli dA-dT/química , Poli dA-dT/metabolismo , Profármacos/uso terapéutico , Profármacos/toxicidad , Ratas , Relación Estructura-Actividad , Temperatura de Transición , Trypanosoma brucei rhodesiense/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológicoRESUMEN
BACKGROUND: Malaria, trypanosomiasis and leishmaniasis have an overwhelming impact in the poorest countries in the world due to their prevalence, virulence and drug resistance ability. Currently, there is inadequate armory of drugs for the treatment of malaria, trypanosomiasis and leishmaniasis. This underscores the continuing need for the discovery and development of new anti-protozoal drugs. Consequently, there is an urgent need for research aimed at the discovery and development of new effective and safe anti-plasmodial, anti-trypanosomal and anti-leishmanial drugs. METHODS: Bioassay-guided chromatographic fractionation was employed for the isolation and purification of antiprotozoal alkaloids. RESULTS: The methanol extract from the leaves of Annickia kummeriae from Tanzania exhibited a strong anti-plasmodial activity against the multi-drug resistant Plasmodium falciparum K1 strain (IC50 0.12 ± 0.01 µg/ml, selectivity index (SI) of 250, moderate activity against Trypanosoma brucei rhodesiense STIB 900 strain (IC50 2.50 ± 0.19 µg/ml, SI 12) and mild activity against Leishmania donovani axenic MHOM-ET-67/82 strain (IC50 9.25 ± 0.54 µg/ml, SI 3.2). Bioassay-guided chromatographic fractionation led to the isolation of four pure alkaloids, lysicamine (1), trivalvone (2), palmatine (3), jatrorrhizine (4) and two sets of mixtures of jatrorrhizine (4) with columbamine (5) and palmatine (3) with (-)-tetrahydropalmatine (6). The alkaloids showed low cytotoxicity activity (CC50 30 - >90 µg/ml), strong to moderate anti-plasmodial activity (IC50 0.08 ± 0.001 - 2.4 ± 0.642 µg/ml, SI 1.5-1,154), moderate to weak anti-trypanosomal (IC50 2.80 ± 0.001 - 14.3 ± 0.001 µg/ml, SI 2.3-28.1) and anti-leishmanial activity IC50 2.7 ± 0.001 - 20.4 ± 0.003 µg/ml, SI 1.7-15.6). CONCLUSION: The strong anti-plasmodial activity makes these alkaloids good lead structures for drug development programs.
Asunto(s)
Annonaceae/química , Antiprotozoarios/farmacología , Aporfinas/farmacología , Alcaloides de Berberina/farmacología , Leishmania donovani/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Antimaláricos/análisis , Antimaláricos/farmacología , Antiprotozoarios/análisis , Aporfinas/análisis , Alcaloides de Berberina/análisis , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Concentración 50 Inhibidora , Fitoterapia , Extractos Vegetales/análisis , Extractos Vegetales/farmacología , Hojas de la Planta , Infecciones por Protozoos/tratamiento farmacológico , Tanzanía , Tripanocidas/análisis , Tripanocidas/farmacologíaRESUMEN
New analogs of the antiprotozoal agent Furamidine were prepared utilizing Stille coupling reactions and amidation of the bisnitrile intermediate using lithium bis-trimethylsilylamide. Both the phenyl groups and the furan moiety of furamidine were replaced by heterocycles including thiophene, selenophene, indole or benzimidazole. Based upon the ΔTm and the CD results, the new compounds showed strong binding to the DNA minor groove. The new analogues are also more active both in vitro and in vivo than furamidine. Compounds 7a, 7b, and 7f showed the highest activity in vivo by curing 75% of animals, and this merits further evaluation.
Asunto(s)
Antiprotozoarios , Benzamidinas , Animales , Benzamidinas/farmacología , Benzamidinas/química , Benzamidinas/metabolismo , Antiprotozoarios/farmacología , ADN/metabolismoRESUMEN
A series of phenyl-2,2'-bichalcophene diamidines 1a-h were synthesized from the corresponding dinitriles either via a direct reaction with LiN(TMS)2, followed by deprotection with ethanolic HCl or through the bis-O-acetoxyamidoxime followed by hydrogenation in acetic acid and EtOH over Pd-C. These diamidines show a wide range of DNA affinities as judged from their ΔT(m) values which are remarkably sensitive to replacement of a furan unit with a thiophene one. These differences are explained in terms of the effect of subtle changes in geometry of the diamidines on binding efficacy. Five of the eight compounds were highly active (below 6 nM IC50) in vitro against Trypanosoma brucei rhodesiense (T. b. r.) and four gave IC50values less than 7 nM against Plasmodium falciparum (P. f.). Only one of the compounds was as effective as reference compounds in the T. b. r. mouse model for the acute phase of African trypanosomiasis.
Asunto(s)
Antiprotozoarios/química , Pentamidina/química , Tripanosomiasis Africana/tratamiento farmacológico , Animales , Antiprotozoarios/síntesis química , Antiprotozoarios/uso terapéutico , Modelos Animales de Enfermedad , Ratones , Pentamidina/síntesis química , Pentamidina/uso terapéutico , Plasmodium falciparum/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacosRESUMEN
Analogs of the trypanocidal lead compound 1-benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-yl acetate were prepared to extend the structure-activity relationship in this series of molecules, improve the in vivo antitrypanosomal activity of the lead, and determine whether ester prodrugs are needed to overcome the instability of the dihydroquinolin-6-ols. Two of the most active compounds identified in this study were 1-benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-ol hydrochloride and 1-(2-methoxy)benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-ol hydrochloride. These stable solids possessed low nanomolar IC(50) values against Trypanosoma brucei rhodesiense STIB900 in vitro and provided cures in an early treatment acute mouse model of African trypanosomiasis when given ip at 50mg/kg/day for four consecutive days.
Asunto(s)
Quinolinas/síntesis química , Quinolinas/farmacología , Tripanocidas/síntesis química , Tripanocidas/farmacología , Animales , Ciclización , Ratones , Quinolinas/química , Sales (Química)/química , Relación Estructura-Actividad , Tripanocidas/químicaRESUMEN
The effects of replacing the central furan ring of furamidine with indole and benzimidazole on their DNA binding affinity, antiparasitic activity and fluorescence are reported. The bis-cyanophenylindoles required to make the corresponding amidines were prepared by sequential Stille and/or Suzuki coupling reactions. The bis-cyanophenylbenzimidazoles were obtained by coupling 4-cyanobenzaldehydes with the appropriate cyano substituted phenylenediamine. The bis-nitriles were converted to the diamidines by reaction with LiN[Si(CH(3))(3)](2) or by Pinner methodology. Specifically, we have prepared new series of 2,6- and 2,5-diaryl indoles (6a,b, 12 and 17a-d) and the related benzimidazoles (24, 30 and 35). The new compounds bind in the DNA minor groove in DNA AT base pair sequences and eight of the ten new analogues exhibit ΔT(m) values comparable to or higher than that of furamidine. Six of ten of the new compounds exhibit lower IC(50) values against Trypanosoma brucei rhodesiense (T. b. r.) and eight of ten exhibit lower IC(50) values against Plasmodium falciparum (P. f.) than furamidine. Four of the ten show greater efficacy than furamidine in the rigorous T. b. r. STIB900 mouse model for African trypanosomiasis. Generally, the fluorescence properties of the new analogues are similar to that of DAPI.
Asunto(s)
Antiparasitarios/farmacología , Antiprotozoarios/síntesis química , Antiprotozoarios/farmacología , Benzamidinas/síntesis química , Benzamidinas/farmacología , ADN Protozoario/efectos de los fármacos , Animales , Antiparasitarios/uso terapéutico , Antiprotozoarios/química , Benzamidinas/química , Bencimidazoles/síntesis química , Bencimidazoles/química , Bencimidazoles/farmacología , Dicroismo Circular , Reactivos de Enlaces Cruzados/química , ADN Protozoario/metabolismo , Fluorescencia , Humanos , Ratones , Modelos Químicos , Estructura Molecular , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/genética , Relación Estructura-Actividad , Trypanosoma brucei rhodesiense/efectos de los fármacos , Trypanosoma brucei rhodesiense/genéticaRESUMEN
The molecular mechanisms of K(+) homeostasis are only poorly understood for protozoan parasites. Trypanosoma brucei subsp. parasites, the causative agents of human sleeping sickness and nagana, are strictly extracellular and need to actively concentrate K(+) from their hosts' body fluids. The T. brucei genome contains two putative K(+) channel genes, yet the trypanosomes are insensitive to K(+) antagonists and K(+) channel-blocking agents, and they do not spontaneously depolarize in response to high extracellular K(+) concentrations. However, the trypanosomes are extremely sensitive to K(+) ionophores such as valinomycin. Surprisingly, T. brucei possesses a member of the Trk/HKT superfamily of monovalent cation permeases which so far had only been known from bacteria, archaea, fungi, and plants. The protein was named TbHKT1 and functions as a Na(+)-independent K(+) transporter when expressed in Escherichia coli, Saccharomyces cerevisiae, or Xenopus laevis oocytes. In trypanosomes, TbHKT1 is expressed in both the mammalian bloodstream stage and the Tsetse fly midgut stage; however, RNA interference (RNAi)-mediated silencing of TbHKT1 expression did not produce a growth phenotype in either stage. The presence of HKT genes in trypanosomatids adds a further piece to the enigmatic phylogeny of the Trk/HKT superfamily of K(+) transporters. Parsimonial analysis suggests that the transporters were present in the first eukaryotes but subsequently lost in several of the major eukaryotic lineages, in at least four independent events.
Asunto(s)
Proteínas de Transporte de Catión/metabolismo , Potasio/metabolismo , Proteínas Protozoarias/metabolismo , Trypanosoma brucei brucei/metabolismo , Animales , Proteínas de Transporte de Catión/clasificación , Proteínas de Transporte de Catión/genética , Línea Celular , Humanos , Datos de Secuencia Molecular , Oocitos/citología , Oocitos/fisiología , Técnicas de Placa-Clamp , Fenotipo , Filogenia , Proteínas Protozoarias/clasificación , Proteínas Protozoarias/genética , Interferencia de ARN , Trypanosoma brucei brucei/citología , Trypanosoma brucei brucei/genética , Moscas Tse-Tse/metabolismo , Moscas Tse-Tse/parasitología , Xenopus laevisRESUMEN
Dicationic diamidines have been well established as potent antiparasitic agents with proven activity against tropical diseases like trypanosomiasis and malaria. This work presents the synthesis of new mono and diflexible triaryl amidines (6a-c, 13a,b and 17), their aza analogues (23 and 27) and respective methoxyamidine prodrugs (5, 7, 12a,b, 22 and 26). All diamidines were assessed in vitro against Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium falciparum (P. f.) where they displayed potent to moderate activities at the nanomolar level with IC50s = 11-378 nM for T. b. r. and 4-323 nM against P. f.. In vivo efficacy testing against T. b. r. STIB900 has shown the monoflexible diamidine 6c as the most potent derivative in this study eliciting 4/4 cures of infected mice for a treatment period of >60 days upon a 4 × 5 mg/kg dose i. p. treatment. Moreover, thermal melting analysis measurement ΔTm for this series of diamidines/poly (dA-dT) complexes fell between 0.5 and 19 °C with 6c showing the highest binding to the DNA minor groove. Finally, a 50 ns molecular dynamics study of an AT-rich DNA dodecamer with compound 6c revealed a strong binding complex supported by vdW and electrostatic interactions.
Asunto(s)
Amidinas/farmacología , Antiparasitarios/farmacología , Compuestos Aza/farmacología , Plasmodium falciparum/efectos de los fármacos , Profármacos/farmacología , Trypanosoma brucei rhodesiense/efectos de los fármacos , Amidinas/síntesis química , Amidinas/química , Antiparasitarios/síntesis química , Antiparasitarios/química , Compuestos Aza/síntesis química , Compuestos Aza/química , Relación Dosis-Respuesta a Droga , Modelos Moleculares , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Profármacos/síntesis química , Profármacos/química , Relación Estructura-Actividad , Trypanosoma brucei rhodesiense/enzimologíaRESUMEN
Seven novel diamidino 2,5-bis(aryl)thiazoles (5a-g) were synthesized and evaluated against Trypanosoma brucei rhodensiense (T. b. r.) and Plasmodium falciparum (P. f.). The diamidines were obtained directly from the corresponding bis-nitriles (4a-g) by the action of lithium bis(trimethylsilyl)amide. The bis-nitriles 4a-f were synthesized in four steps starting with the Stille coupling of 2-tributyltinthiazole with the appropriate cyanoaryl halide. The bis-nitrile 5g was obtained by the palladium facilitated coupling of the mixed tin-silyl reagent 2-trimethylsilyl-5-trimethyltinthiazole with 2-bromo-5-cyanopyridine. The amidoxime potential prodrugs 6a-e, 6g were obtained by the reaction of hydroxylamine with the bis-nitriles. O-Methylation of the amidoximes gave the corresponding N-methoxyamidines 7a-c, 7e, 7g. The diamidines showed strong DNA binding affinity as reflected by DeltaT(m) measurements. Four of the diamidines 5a, 5b, 5d and 5e were highly active in vitro against P. f. giving IC(50) values between 1.1 and 2.5nM. The same four diamidines showed IC(50) values between 4 and 6nM against T. b. r. The selectivity indices ranged from 233 to 9175. One diamidine 5a produced one of four cures at an ip dose of 4x5mg/kg in the STIB900 mouse model for acute African trypanosomiasis. The amidoxime and N-methoxyamidine of 5a were the only produgs to provide cures (1/4 cures) in the same mouse model on oral dosage at 4x25mg/kg.
Asunto(s)
Antimaláricos/uso terapéutico , Antiprotozoarios/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Tiazoles/uso terapéutico , Tripanosomiasis Africana/tratamiento farmacológico , Administración Oral , Animales , Antiprotozoarios/síntesis química , ADN Protozoario/química , Modelos Animales de Enfermedad , Estabilidad de Medicamentos , Ratones , Pruebas de Sensibilidad Parasitaria , Pentamidina/síntesis química , Pentamidina/uso terapéutico , Plasmodium falciparum/efectos de los fármacos , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Tiazoles/síntesis química , Tripanocidas/uso terapéutico , Trypanosoma brucei brucei/efectos de los fármacosRESUMEN
A novel series of extended DAPI analogues were prepared by insertion of either a carbon-carbon triple bond (16a-d) or a phenyl group (21a,b and 24) at position-2. The new amidines were evaluated in vitro against both Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium falciparum (P. f.). Five compounds (16a, 16b, 16d, 21a, 21b) exhibited IC(50) values against T. b. r. of 9nM or less which is two to nine folds more effective than DAPI. The same five compounds exhibited IC(50) values against P. f. of 5.9nM or less which is comparable to that of DAPI. The fluorescence properties of these new molecules were recorded, however; they do not offer any advantage over those of DAPI.
Asunto(s)
ADN Protozoario/efectos de los fármacos , Fluorescencia , Indoles/síntesis química , Indoles/farmacología , Plasmodium falciparum/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Sitios de Unión , Células Cultivadas , ADN Protozoario/química , Evaluación Preclínica de Medicamentos , Indoles/química , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , RatasRESUMEN
African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829 (CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypanosoma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain (AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug.
Asunto(s)
Benzamidinas/uso terapéutico , Tripanocidas/uso terapéutico , Tripanosomiasis Africana/tratamiento farmacológico , Animales , Benzamidinas/administración & dosificación , Benzamidinas/química , Benzamidinas/farmacología , Sistema Nervioso Central/parasitología , Femenino , Furanos/administración & dosificación , Furanos/química , Furanos/farmacología , Furanos/uso terapéutico , Ratones , Estructura Molecular , Tripanocidas/administración & dosificación , Tripanocidas/química , Tripanocidas/farmacología , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma brucei brucei/patogenicidad , Trypanosoma brucei gambiense/efectos de los fármacos , Trypanosoma brucei gambiense/patogenicidad , Trypanosoma brucei rhodesiense/efectos de los fármacos , Trypanosoma brucei rhodesiense/patogenicidad , Tripanosomiasis Africana/parasitologíaRESUMEN
A series of azaterphenyl diamidines has been synthesized and evaluated for in vitro antiprotozoal activity against both Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium falciparum (P. f.) and in vivo efficacy in the STIB900 acute mouse model for T. b. r. Six of the 13 compounds showed IC(50) values less than 7 nM against T. b. r. Twelve of those exhibited IC(50) values less than 6 nM against P. f. and six of those showed IC(50) values 0.6 nM, which are more than 25-fold as potent as furamidine. Moreover, two of them showed more than 40-fold selectivity for P. f. versus T. b. r. Three compounds 15b, 19d and 19e exhibited in vivo efficacy against T. b. r. much superior to furamidine, and equivalent to or better than azafuramidine. The antiparasitic activity of these diamidines depends on the ring nitrogen atom(s) location relative to the amidine groups and generally correlates with DNA binding affinity.
Asunto(s)
Antiprotozoarios/química , Antiprotozoarios/uso terapéutico , Pentamidina/análogos & derivados , Pentamidina/uso terapéutico , Plasmodium falciparum/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Animales , Antiprotozoarios/farmacología , Concentración 50 Inhibidora , Malaria Falciparum/tratamiento farmacológico , Ratones , Pruebas de Sensibilidad Parasitaria , Pentamidina/farmacología , Relación Estructura-Actividad , Tripanosomiasis Africana/tratamiento farmacológicoRESUMEN
The unicellular parasite Trypanosoma brucei is transmitted between mammals by tsetse flies. Following the discovery that flagellar phosphodiesterase PDEB1 is required for trypanosomes to move in response to signals in vitro (social motility), we investigated its role in tsetse flies. Here we show that PDEB1 knockout parasites exhibit subtle changes in movement, reminiscent of bacterial chemotaxis mutants. Infecting flies with the knockout, followed by live confocal microscopy of fluorescent parasites within dual-labelled insect tissues, shows that PDEB1 is important for traversal of the peritrophic matrix, which separates the midgut lumen from the ectoperitrophic space. Without PDEB1, parasites are trapped in the lumen and cannot progress through the cycle. This demonstrates that the peritrophic matrix is a barrier that must be actively overcome and that the parasite's flagellar cAMP signaling pathway facilitates this. Migration may depend on perception of chemotactic cues, which could stem from co-infecting parasites and/or the insect host.